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Abstract 
Aims To assess the role played by carbohydrates, fat and proteins in the management 
of Type 2 diabetes. 
 
Background Diabetes research tends to reflect the interests of academics or the 
pharmaceutical industry, rather than those of people living with Type 2 diabetes. The 
James Lind Alliance and Diabetes UK addressed this issue by defining the research 
priorities of people living with Type 2 diabetes. Three of the top 10 research priority 
questions focused on lifestyle.  
 
Methods A narrative review was undertaken with a structured search strategy using 
three databases. Search terms included the three macronutrients and Type 2 diabetes. 
No restrictions were placed on macronutrient quantity or length of study follow-up. 
Outcomes included changes in HbA1c, body weight, insulin sensitivity and cardiovascular 
risk. 
Results There is no strong evidence that there is an optimal ratio of macronutrients for 
improving glycaemic control or reducing cardiovascular risk. Challenges included 
defining the independent effect of macronutrient manipulation and identifying the 
effects of macronutrients, independent of foods and dietary patterns. Extreme intakes 
of macronutrients may be associated with health risks. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Conclusions It is challenging to formulate food-based guidelines from studies based on 
macronutrient manipulation. Structured education should be offered to support individuals 
in discovering their optimal, individual dietary approach. Recommendations for dietary 
guidelines should be expressed in terms of foods and not macronutrients. 
 
Introduction 
Type 2 diabetes has been described as a global epidemic, affecting ~382 million people in 2017 
(8.8% of the adult population), and is predicted to rise to 575 million people affected by 2045 [1]. 
In the UK in 2016, it was estimated that 3.8 million people were living with Type 2 diabetes, 
effectively doubling the prevalence over the past 20 years [2]. The prevention and management 
of Type 2  diabetes is complex and encompasses diet, physical activity, medication, weight 
control, management of diabetes-related complications, including cardiovascular risk reduction, 
and self-monitoring. There is a clear need for more research in diabetes [3], but often the 
priorities of people living with a disease are overlooked in favour of those of the pharmaceutical 
industry or academic researchers [4]. 
 
The James Lind Alliance was established to address the inequities in these priorities, and does 
this by bringing together people with a diagnosed specific condition, carers and health 
professionals in order to explore the uncertainties relating to that condition and to define 
research priorities [5]. This process has been conducted in people with Type 1  diabetes [6], and 
more recently in Type 2  diabetes [7]. The top 10 research priorities identified in Type 2 diabetes 
included a variety of topics, and lifestyle factors were mentioned specifically in three of the 10 
research questions. 
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Successful diabetes management requires effective self-management, including dietary 
manipulation. Globally, diabetes associations have attempted to provide evidence-based 
dietary guidelines for the management of diabetes [8–10], including those recently 
published from Diabetes UK [11]. However, for many people with diabetes, there remains a 
degree of confusion about the most appropriate diet for optimizing glycaemic control, for 
weight management and for cardiovascular disease (CVD) risk reduction. The majority of 
authorities recommend a balanced or healthy diet for diabetes, yet the media is full of 
advice about low-carbohydrate, high-fat and high-protein diets. This confusion appeared to 
be reflected in the top 10 research priorities from the James Lind Alliance, and at number 10 
was the question ‘What role do carbohydrates, fats and proteins have in the management of 
Type 2 diabetes, and are there risks and benefits associated with particular approaches?’ 
This review aims to explore and answer this question. 
 
Methods 
Conducting meta-analyses and systematic reviews of dietary intervention studies presents many 
challenges, including heterogeneity in terms of trial design, length of follow-up, type and 
intensity of intervention, comparator diet, duration of diabetes and use of medication. In 
addition, there are areas where many systematic reviews have already been published (low-
carbohydrate diets) and some areas where there is little research in people with Type 2 
diabetes (high-fat and high-protein diets). For these reasons, a formal systematic review with 
meta-analysis was not conducted for this article, and a narrative review using available 
evidence from published reviews and individual studies was undertaken. 
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Electronic databases including Medline, Embase and the Cochrane Central Register of 
Controlled Trials were searched from 1980 (when HbA1c was routinely used to assess 
glycaemic control) to 31 May 2018 to identify suitable meta-analyses, systematic 
reviews and randomized controlled trials (RCTs). Key search terms included 
combinations and synonyms of Type 2 diabetes mellitus, diet*, carbohydrate, glyc*, 
index, fibre, protein, amino acids, fat*, saturat* and unsaturat*. There was no 
restriction on amount of macronutrient included in the dietary intervention and length 
of follow-up, and outcomes included changes in HbA1c, body weight, insulin sensitivity 
and CVD risk. 
 
Definitions of high, moderate and low intakes of macronutrients are not universally 
agreed, and, for the purposes of the present analysis, the definitions adopted are 
shown in Table 1 [12]. 
 
Results 
Carbohydrate 
Dietary carbohydrate in the management of Type 2 diabetes continues to be the subject 
of debate amongst both the popular media and within clinical and academic arenas. 
Nutrition guidelines for Type 2 diabetes in the UK have not made a specific 
recommendation for carbohydrate since 2011, but instead encourage an individualized 
approach to carbohydrate intake and focus on weight loss in the overweight [11]. It is 
estimated that the typical diet consumed in the UK contains ~47% of total energy intake 
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from carbohydrate [13] and that people with Type 2 diabetes consume a similar 
amount, but still at a level that could be classified as ‘high carbohydrate’ [14]. 
 
Table 2 summarizes recent systematic reviews and meta-analyses of carbohydrate 
quantity in Type 2 diabetes. RCTs and systematic reviews are frequently associated with 
a common set of methodological concerns. These include the failure to measure the 
pre-study dietary intake of participants, the use of grams of carbohydrate vs percentage 
of total energy intake from carbohydrate and the definitions used to categorize high- or 
low-carbohydrate diets. 
 
Glycaemic control 
Carbohydrate quantity. Dietary carbohydrate is the only macronutrient which has a direct 
and immediate effect on postprandial blood glucose levels [15]. Yet, despite a large volume 
of published research on the subject, and including many systematic reviews and meta 
analyses, there is still no clear conclusion regarding the optimal quantity of carbohydrate for 
glycaemic control in Type 2 diabetes [16–24]. This lack of a definitive conclusion may have 
contributed to the confusion and lack of understanding reported in some people with Type 2 
diabetes [25], and to the lack of a consistent approach in the advice given by registered 
dietitians [26]. 
 
High-carbohydrate diets (>45% total energy intake from carbohydrate or >225g 
carbohydrate per day) typically represent ‘healthy’ or ‘prudent’ eating patterns and are 
recommended for the general population. One challenge of using either %total energy intake 
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or absolute amount of carbohydrate was demonstrated in the Look AHEAD trial, in which the 
dietary intervention provided 50.8% total energy intake from carbohydrate [27], although, as 
total energy intake was restricted to induce weight loss, the absolute amount of 
carbohydrate met the definition of a moderate carbohydrate diet. 
 
Nine recent systematic reviews and meta-analyses of the effects of carbohydrate restriction 
on HbA1c considered in the present review consistently reported a short-term improvement, 
maintained over 6–12 months, but which was not maintained over the longer term [16–24]. 
Of the seven meta-analyses, five reported statistically greater reductions in HbA1c for 
restricted carbohydrate diets, but these were modest and typically in the order of 1–5 
mmol/mol [16,19–24], with one reporting a reduction of 9 mmol/mol [23]. Two systematic 
reviews reported equivocal results, with larger numbers of included trials failing to 
demonstrate superiority of low-carbohydrate diets [17,18]. A variety of definitions for 
carbohydrate restriction/low-carbohydrate diets were used, and prescribed intakes ranged 
from 20 to 225 g per day (<10–45% total energy intake). This is important because moderate 
restriction (26–40% total energy intake) does not appear to reduce glycaemia significantly 
[22,24]. 
 
Evidence for clinical benefits of very-low-carbohydrate diets (<50 g per day) was lacking in 
the reviews. Studies that measured and reported end-of-study carbohydrate intake stated 
that the assigned dietary prescription was rarely adhered to in long-term trials. For example, 
in a meta-analysis of very-low-carbohydrate, ketogenic diets (<50 g/day) in people without 
diabetes, prescribed intake from carbohydrate was achieved in only one study out of 13 [28]. 
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To reiterate, caution is required when interpreting biochemical and physiological efficacy 
from long-term randomized dietary trials where adherence is a concern [29].  
 
It is challenging to separate the effects of carbohydrate restriction independently of 
weight loss because most of the trials included in the meta-analyses do not ensure 
study arms are isocaloric, and therefore differences in weight loss between diets may 
be contributing to effects on glycaemic control. One systematic review attempted to 
address this issue by comparing studies in which there were no differences in weight 
loss between groups, but the authors were still unable to conclude that a particular 
balance of macronutrients or one dietary pattern was superior to any other [18]. Only 
one of the meta-analyses of low-carbohydrate diets reported significant differences in 
weight between restricted- and higher-carbohydrate diets, and it appeared that any 
short-term improvements in glycaemic control were attributable solely to weight loss, 
with no significant differences between diets with equal weight loss [22]. 
 
These data suggest that carbohydrate restriction reduces HbA1c more than control diets 
over the short term (6–12 months), but not the longer term, and reductions in 
medication are associated with carbohydrate restriction [18,22]; however, beyond the 
absolute amount of carbohydrate, or its percentage contribution to energy, are wider 
questions about dietary quality. Dietary patterns such as Mediterranean-style diets and 
vegetarian and vegan diets have led to improvements in glycaemic control, weight loss 
and reduced CVD risk, despite providing moderate to high intakes of carbohydrate 
[30,31] 
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Carbohydrate quality. Glycaemic index is a measure of the glycaemic response to a 
carbohydrate-containing food relative to a test food and has been the subject of 
significant research over many years. More recent systematic reviews and meta-
analyses indicate decreasing significance of this dietary approach. Earlier meta-analyses 
concluded that low glycaemic index diets reduce HbA1c by ~6 mmol/mol [32], although 
recent reviews report more modest reductions of 2–5 mmol/mol [33,34]. The most 
recent meta-analysis included papers over a shorter time period and therefore included 
fewer research studies in the analysis [34]. Methodological challenges are prevalent in 
this area as with other areas of carbohydrate research, including the potential for large 
variations in the glycaemic index values of a given food and the fact that most people 
consume moderate rather than high glycaemic index diets, which are commonly used as 
comparison diets in studies. Overall, the volume of research indicates a small but 
statistically significant benefit for low glycaemic index dietary patterns, although the 
overall clinical significance is open to question. 
 
Studies of dietary fibre and its effects on glycaemic control in Type 2 diabetes typically 
use fibre supplementation in the form of guar gum, psyllium or food sources of cereal 
and wheat fibre in order to achieve the levels of fibre intake associated with significant 
effect. The most recent review of fibre comprised a review of 16 meta-analyses, five of 
which specifically addressed HbA1c outcomes, and all but one reported a significant 
reduction [35]. Reported reductions in HbA1c ranged from 2 to 6 mmol/mol (0.2–0.5%), 
and all trials used supplementation with either β-glucan (3–3.5 g/day) or soluble fibre 
(15–16 g/day). It is unclear whether evidence derived from supplementation translates 
to increased dietary fibre without the use of supplementation, but there is clearly a role 
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for fibre in the diets of people with Type 2 diabetes, not least because the majority of 
people in the UK do not meet the recommended intakes of dietary fibre [36]. The 
positive effects on glycaemia of both low glycaemic index and high-fibre diets appear to 
occur independently of weight loss. 
 
Sugars 
Free sugars are defined as those added in the manufacture and preparation of food, and 
those added by the consumer, and include the sugars found in fruit juice, syrups and honey 
[37]. Traditionally table sugar (sucrose) has been restricted for people with Type 2 diabetes. 
Misunderstanding regarding the role of sugar in glycaemia may stem from previous 
characterization of carbohydrates into complex and simple sugars. In fact, the fructose 
component of the disaccharide sucrose gives this disaccharide a lower glycaemic index than 
some starches. Most studies show that isocaloric replacement of starch with fructose lowers 
glycaemia without any adverse cardiometabolic effects [38]. 
 
Cardiovascular disease risk 
A major concern regarding low-carbohydrate diets has been a potential increase in CVD risk 
associated with increased fat intake. In general, trials of low-carbohydrate diets show a 
reduction in triglycerides, an increase in HDL cholesterol, and a reduction in blood pressure 
[21]. The effects on triglycerides and HDL cholesterol may occur independently of weight 
loss. It has been suggested that the LDL cholesterol-raising effects of foods high in saturated 
fat is not observed when carbohydrate is restricted, and that carbohydrate restriction per se 
improves the atherogenic risk profile specifically by reducing small, dense LDL particles [39]. 
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However, in common with the positive effects seen on glycaemic control, dietary patterns 
such as Mediterranean-style diets and vegetarian diets, which provide moderate to high 
amounts of carbohydrate, are associated with reduced CVD risk [30,31]. 
 
Risks and benefits 
Low-carbohydrate diets are effective for improvements in glycaemic control and for weight 
reduction in people with Type 2 diabetes, but there is no conclusive evidence of long-term 
benefit when compared with other dietary strategies, which is probably the result of lack of 
adherence in long-term trials Low-carbohydrate diets may be lower in fibre, however, which 
may increase the risk of gastrointestinal problems, including constipation [40]. The long-term 
effects of carbohydrate restriction on the gut microbiome are unknown, and may have 
implications for long-term colonic health. It is possible that a carbohydrate-restricted diet 
may be less diverse than a high-carbohydrate diet, but it should be emphasized that well-
formulated low- and high-carbohydrate diets can both be varied. 
 
Fat 
Dietary fat has been long been a focus of interest because of the diet–heart hypothesis, 
linking intake of saturated fatty acids (SFAs) to CVD and its associated risk factors, most 
notably serum cholesterol [41]. This is particularly relevant to people with Type 2 diabetes 
as they are at greater risk of developing CVD; however, there are few studies in people with 
Type 2 diabetes investigating low-fat interventions and CVD outcomes, and 
recommendations are largely extrapolated from other groups at high risk of CVD. 
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Glycaemic control and insulin metabolism 
The role of dietary fat in glycaemic control appears to be related to its action on insulin 
sensitivity and insulin resistance [42] and to insulin response, although it is much less 
pronounced than that seen after the consumption of carbohydrate  
[43]. In general, data suggest that replacement of SFA with unsaturated fat can improve 
insulin sensitivity [42]. 
 
Fat and cardiovascular disease risk 
The role of dietary fat in the management of Type 2 diabetes remains an area of 
controversy and debate. Although the majority of authorities continue to support 
substitution of SFAs by unsaturated fat [44], others have proposed that dietary fat has 
been incorrectly demonized and labelled as the primary dietary driver of CVD [45], and 
that the widespread consumption of low-fat, high-carbohydrate processed foods are 
causally associated with increased obesity and Type 2 diabetes [45,46]. This view is not 
consistently supported by the available literature [44]. 
 
Amount of fat 
Dietary recommendations for total fat intake in the UK have not been reviewed since the 
1990s and recommend that dietary fat should supply <30–35% of total energy intake [47]. A 
recent review by the European Food Safety Agency retained this upper limit, but added a 
lower recommendation for intake of at least 20% total energy intake from fat [48]. Diabetes 
UK do not recommend a specific amount of dietary fat for people with Type 2 diabetes 
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because of contradictory evidence from published studies [49]. It is apparent that in 
many clinical studies, a low-fat diet (≤30% total energy intake) is effective in the 
treatment of Type 2 diabetes [49]. Nevertheless, in the Look AHEAD trial, this strategy 
failed to show a significant reduction in cardiovascular mortality, despite significant 
weight loss and improvements in both glycaemic control and CVD risk factors in the 
intervention group [50]. Conversely, the Prevention with Mediterranean Diet 
(PREDIMED) study (with nearly 50% of the cohort with Type 2 diabetes) reported a 
significant reduction in CVD mortality with a higher-fat diet (40% total energy intake), 
although the majority of fat was monounsaturated [30,51]. It is likely that the type, 
rather than the amount, of dietary fat is of greater importance for CVD risk reduction in 
people with Type 2 diabetes [52]. 
 
Type of fat 
Restriction of SFAs has been the mainstay of past dietary recommendations and the UK 
Scientific Advisory Committee on Nutrition has recently published a draft document 
recommending that the dietary reference value for SFAs for the general population remain 
unchanged at no more than 10% total energy intake, and that SFAs should be substituted with 
unsaturated fats [44]. This recommendation is supported by Diabetes UK [11], although for 
people with Type 2 diabetes there is very little published evidence investigating the effects of 
different kinds of fat on CVD risk, with the notable exception of monounsaturated fatty acids. 
A meta-analysis of RCTs in people with Type 2 diabetes reported positive effects of 
Mediterranean-style diets, rich in monounsaturated fatty acids, on glycaemic control and CVD 
risk [30]. 
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Despite contradictory opinion about the role of saturated fat and CVD risk [53], there is no 
evidence to recommend increasing SFA intake to improve glycaemic control or CVD risk for 
people with Type 2 diabetes [49]. A common feature of many studies is that the dietary 
intervention applied included the recommendation of <10% total energy intake derived from 
SFAs, independent of the total percentage energy derived from fat, so there is little available 
evidence of the independent effect of high-fat/high-SFA diets. 
 
Risks and benefits 
Low-fat diets. Beneficial outcomes of low-fat diets for people with Type 2 diabetes are reported 
in some RCTs [50], but not all [54], and, as a result, these diets are now recommended as only one 
of a number of dietary strategies suitable for those with Type 2 diabetes. Evidence suggests that 
the type of carbohydrate used to replace fat in low-fat diets also has a role, with increased risk of 
CVD associated with increased processed or refined carbohydrate and reduced risk associated 
with wholegrain and unprocessed carbohydrate [56]. For most people with Type 2 diabetes 
who are overweight or obese, weight loss is the primary aim and it is challenging to assess the 
effects of manipulation of dietary fat independently of weight loss. A recent review reported 
that weight losses of 10% in people with Type 2 diabetes reduce cardiovascular events by 
21%, independent of the dietary strategy used to achieve weight loss [57]. 
 
High-fat diets. It has been suggested that high-fat diets (>40% total energy intake) help 
reduce appetite and aid weight loss, but these studies were carried out in the general 
populations and not specifically people with diabetes [58]. High-fat diets are usually 
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associated with lower carbohydrate intake, and replacement of carbohydrate with fat 
lowers the postprandial insulin demand. 
 
The major concern associated with high-fat, low-carbohydrate diets is that of increased CVD 
risk, and some deleterious effects have been reported. Higher intakes of SFAs do elevate 
plasma LDL cholesterol, but this is only a small part of CVD risk, and diets providing 
dietary fat as unsaturated fat do not appear to increase CVD risk [56]. 
 
Protein 
There is no specific recommendation for protein in the management of Type 2 diabetes 
[8,11]. Compared with carbohydrate and fat, dietary protein has been less of a focus in 
the management of Type 2 diabetes [8,11], and relatively less well studied [16]. While 
carbohydrate is the macronutrient with the largest effect on postprandial glycaemia, 
protein may also play an important role in the long-term management of Type 2 
diabetes because of the insulinogenic effect on the β cell [59]. In this section, we discuss 
the effect of protein on glycaemic control and cardiovascular risk factors [60] including 
intrahepatic triglyceride stores [61]. 
 
Glycaemia 
Current guidelines in the UK suggest a protein intake of 0.75 g of protein per kg or 10–15% 
total energy intake [47]. In most studies, 20–30% total energy intake from protein is used in 
the high-protein arm [16,60]. Two meta-analyses were published in 2013, and compared 
the effects of high-protein diets with lower-protein diets on weight, glycaemic control and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
cardiovascular risk factors in adults with Type 2 diabetes [16,60]. The first meta-analysis 
included RCTs of >6 months in length and found that only two studies met their inclusion 
criteria [16]. Both these studies compared a high-protein diet (30% total energy intake from 
protein, 40% total energy intake from carbohydrate) with low-protein diets (15% total 
energy intake from protein, 55% total energy intake from carbohydrate) and reported 
significant reductions in HbA1c (Table 3). The second meta-analysis included studies of >4 
weeks' duration, specified a high-protein diet as >20% total energy intake, and stipulated 
a difference of >5% total energy intake from protein between the intervention and 
control arms [60]. This meta-analysis also found a significant pooled reduction in HbA1c. 
Moderate to high heterogeneity was observed in both meta-analyses, and a sub-group 
analysis in the latter partly attributed the heterogeneity to differences in baseline 
HbA1c. Weight loss appears to attenuate the effect of added protein on glycaemia, and 
it is likely that, as long as weight loss is achieved, the macronutrient composition of the 
diet is a minor regulatory factor [16, 60]. 
 
An additional factor which may contribute to the heterogeneity is the macronutrient 
composition of the rest of the diet. In one meta-analysis [60], the largest reductions in fasting 
plasma glucose and HbA1c were in the two studies which severely restricted carbohydrates 
(<20% total energy intake) [62,63]. Given complementary findings from low-carbohydrate 
studies (that low-carbohydrate studies with high protein tend to result in lower glycaemia 
than low-carbohydrate diets with low protein), it is possible that a low-carbohydrate, 
moderate-protein diet may be a physiologically optimum dietary protocol for managing 
glycaemia. This hypothesis should be formally tested in a well-designed trial. Since the 
publication of the two meta-analyses, more randomized trials have reported [64–69]. In 
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general, their results are consistent with those of the meta-analyses: a higher proportion of 
protein in the diet appears to have little effect on glycaemia independent of weight loss. 
 
The finding from meta-analyses that high-protein diets may lower HbA1c but not fasting 
glucose [60] may reflect the acute insulinogenic effect of dietary protein [59]. The pancreas 
releases insulin in response to both glucose and amino acids, although sensitivity to both is 
lost as Type 2 diabetes progresses [70]. Acute studies show a dose–response effect of dietary 
protein on glycaemia [71], and short-term trials combining protein with moderate and severe 
carbohydrate restriction reported prandial increases in insulin concentrations associated with 
decreasing blood glucose levels [65,72, 73]. Importantly, these trials provided all study foods 
in order to increase adherence. 
 
Cardiovascular risk factors 
A 2013 meta-analysis that included people with Type 2 diabetes showed that replacement of 
carbohydrate with protein significantly lowered blood pressure, with pooled reductions of ~2 
mmHg and ~1 mmHg observed for systolic and diastolic blood pressure, respectively [74]. 
Importantly, this is observed for both animal and vegetable sources of protein [75]. This meta-
analysis included studies with a range of dietary protocols including protein supplementation, but 
the effect of dietary protein vs protein from supplements does not seem to alter the findings 
[74,75]. The replacement macronutrient is probably important, and the hypotensive effect of 
protein may only be observed when it replaces carbohydrate [16,74,75]. In contrast, the 
quantity of dietary protein does not seem to affect the lipid profile [16,60]. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Source of dietary protein 
The dietary source of protein may not be an important determinant of its antiglycaemic 
or antihypertensive effects [60,74,75]. Both dairy proteins, such as whey and casein, 
and high-protein foods, such as chicken and meat, have all been used in studies 
reporting increased postprandial insulin and reduced blood glucose concentrations 
[16,60]. The effect is probably driven by a reduction in carbohydrate, and by the 
addition of amino acids individually and in combination. Similarly, studies comparing 
animal and vegetable protein show no difference in terms of their antihypertensive 
effects [74,75]. In contrast, the source of protein is an important consideration for 
managing lipidaemia [16], and in this regard general dietary recommendations are 
appropriate: limiting excessive red meat intake, oily fish twice per week, and a variety 
of vegetable protein sources, which are also high in fibre such as pulses, nuts and seeds. 
 
Risks and benefits 
Intrahepatic triglycerides are closely linked to Type 2 diabetes, insulin resistance and 
cardiovascular risk. The available studies are few in number and of varying quality, but 
the data are intriguing and suggest that elevated dietary protein attenuates the 
increased intrahepatic triglyceride levels observed after hypercaloric feeding with 
fructose [76] or fat [77], and that 4 weeks' supplementation with 60 g/day of whey 
protein reduced intrahepatic triglyceride levels in obese women without any 
concomitant reduction, independently of body weight changes [78]. A 6-month 
prospective clinical audit of patients with Type 2 diabetes and non-alcoholic fatty liver 
disease showed a reduction in intrahepatic triglycerides with a high animal or  vegetable 
protein diet (30% total energy intake from protein, 40% total energy intake from 
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carbohydrates) [79]. Other studies have supported these findings but are confounded 
by marked carbohydrate restriction [79,80]. Historically, health concerns regarding 
increasing the protein content of the diet have included accelerated decline in renal 
function [81] and osteoporosis [82] caused by excessive calcium loss. These concerns 
have not been substantiated in trials in individuals with Type 2 diabetes without renal 
disease [81,82]. 
 
Dicusssion 
The James Lind Alliance has shown that people with Type 2 diabetes and health 
professionals alike want to know details of the optimum diet for diabetes, especially 
how much carbohydrate, fat and protein they should eat. This is a question without a 
definitive answer for reasons which include the strategies used to formulate evidenced-
based advice, the fact that it is challenging to determine the effect of a dietary 
intervention independent of weight loss, the fact that manipulating the amount of one 
macronutrient will have an effect on the remaining two macronutrients and the fact 
that there is individual variation in people’s response to different foods and nutrients. 
 
Formulating evidence-based dietary guidelines is a complex, challenging process, and has become 
increasingly demanding as general interest has increased alongside a rapidly expanding science 
base. One of the most challenging aspects is distilling the available evidence into concepts that are 
readily understood and which can be applied in practice by people with diabetes. There is now 
general agreement that food-based rather than nutrient-based guidelines help translate science 
into recommendations that most people understand [83]. The main challenge remains the fact 
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that much of the dietary evidence for people with Type 2 diabetes is derived from studies that 
manipulate macronutrients rather than food. For example, despite data supporting the 
substitution of saturated fat with unsaturated fat in reducing CVD risk [52,53], focusing narrowly 
on the fat content may not include accurate consideration of the nutritional influence of the foods 
containing the fat and the individual’s dietary pattern. Studies have demonstrated the efficacy of 
the Mediterranean-style dietary pattern for CVD prevention where the focus was on incorporating 
olive oil, nuts and seeds, reducing butter and replacing red meat with fish and white meat [51]. 
This food-based approach was successful in meeting nutritional targets for reducing SFAs by 
emphasizing a dietary pattern rather than specific nutrients. Different dietary patterns, including 
Mediterranean-style diets and the DASH (Dietary Approaches to Stop Hypertension) intervention, 
are associated with improved outcomes in people with Type 2 diabetes and, although these diets 
are both plant-based and include similar foods, they have very different amounts of 
macronutrients [30,83], suggesting that specific foods and dietary patterns may have more 
influence than macronutrients. Research that focuses on individual nutrients is limited by 
definition, as it cannot take into account the complexity of interdependence between foods and 
their effects on diabetes outcomes [85]. 
 
In the UK, >90% of people with Type 2 diabetes are overweight or obese and would benefit from 
weight loss [86], and Diabetes UK recommends this as the primary strategy for improving 
glycaemic control and reducing cardiovascular risk [11]. There is no evidence of superiority of one 
weight-loss strategy over another and, for this reason, it is recommended that people with Type 2 
diabetes adopt a dietary approach that suits their lifestyle, that they are able to sustain over the 
long term and that has a positive impact on their quality of life. The contradictory results of some 
studies and media interest combine to cause confusion. This is best illustrated by the recent 
reports of the effects of low-carbohydrate diets. Low-carbohydrate diets are suggested to be 
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the answer to the Type 2 diabetes epidemic, based on the observation that carbohydrate 
foods have the most pronounced effect on postprandial blood glucose levels. However, 
despite the contradictory results of individual RCTs, and, although these diets are effective for 
weight loss and improvements in glycaemic control, most meta-analyses have reported that 
there is either no advantage for glycaemic control when comparing low-carbohydrate diets 
with other strategies over the long term, or that the reductions in HbA1c may be of statistical, 
but not clinical, significance. The same applies to studies comparing low-fat and high-protein 
diets, and it appears that if weight loss is achieved, then the macronutrient content of the 
diet is of minor importance [87]. For this reason, Diabetes UK recommends a variety of 
strategies for weight loss, including low-carbohydrate, energy restriction, low-fat healthy 
eating and Mediterranean-style diets and the key is to individualize advice. 
 
In conclusion, to date, there is no evidence of an optimal amount of dietary 
macronutrients for people with Type 2 diabetes, and most guidelines and 
recommendations emphasize the need for individualization and taking into account 
culture, food availability and personal preference. People with Type 2 diabetes should 
be offered structured education, including nutritional advice, and should be supported 
in their choice of diet for weight loss, if appropriate, and for improving glycaemic 
control and reducing cardiovascular risk. Food-based guidelines are recommended, and 
dietary advice should be expressed in these terms rather than as macronutrients. 
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Table 1 Definition of high or low macronutrient intake as defined in the research 
literature or as consensus definitions 
 Macronutrient g/day % total energy intake 
 Carbohydrate   
 Very-low carbohydrate 20–50 6–10 
 Low carbohydrate <130 <26 
 Moderate carbohydrate 130–225 26–45 
 High carbohydrate >225 >45 
    
 Fat   
 Mean UK fat intake 67–89 30–40 
 Low fat 67 ≤30 
 Recommended lower limit 44 20 
    
 Protein   
 High intake (90th–97th centile in Europe) 85–135 17–27 
 High protein 125 25 
 Proposed upper limit 175 35 
    
Adapted from: Mellor et al. [12]. 
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Table 2. Summary of results of meta-analyses of restricted carbohydrate dietary interventions in people with Type 2 diabetes 
Lead author Year Length of 
Number of 
studies 
Number of 
participants 
Reported outcomes for restricted carbohydrate vs comparator 
diet 
  
follow-up 
months  (n)   
     HbA1c Weight 
     WMD (95% CI), % WMD (95% CI), kg  
       
Ajala et al. [16] 2013 6–24 8 810 –0.12 (–0.24, 0.00) –0.69 (–1.77, 0.39) 
     P = 0.04, I
2
 = 75% P = 0.21 
       
Fan et al. [19] 2016 3–48 10 1080 –0.33 (–0.51, –0.151) –2.35 (–3.65, –1.06) 
     P <0.01, I
2
 = 88.4% P <0.001 
       
Huntriss et al. [20] 2017 12 7 1866 –0.28 (–0.53, –0.02) 0.28 (–1.37, 1.92) 
     P = 0.03, I
2
 = 54% P = 0.74, I
2
 = 75% 
       
Meng et al.  [21] 2017 3–24 9 743 -0.44 (-0.61, –0.26) –0.94kg (–1.92, 0.05) 
     P <0.001, I
2
 = 19.6% P = 0.06, I
2
 35.5% 
       
Sainsbury et al. [22] 2018 12 11 1779 –0.09 (–0.21, 0.03) –0.43kg (–0.93, 0.07) 
     P = 0.12, I
2
 = 16% NS 
       
Schwingshackl et 
al.  [23] 2018 3–24 27 2799 –0.82 (–1.11, –0.52) Not reported 
     
Significance and heterogeneity not 
reported  
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Snorgaard et al. 
[24] 2017 12 7 1376 0.04 (–0.04, 0.13) 0.2 (–0.97, 1.36) 
     P = 0.29, I
2
 = 0% NS 
NS, nonsignificant; WMD, weighted mean difference. 
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Table 3 Summary of recent meta-analyses of quantity of dietary protein in people with Type 2 diabetes 
Lead author Year Length of 
Number of 
studies 
Number of 
participants Reported outcomes for higher- vs lower-protein diets 
  
follow-up, 
months     
     HbA1c Weight 
     WMD (95% CI), % WMD (95% CI), kg 
       
Ajala et al. [16] 2013 12 2 174 –0.28 (–0.38, –0.18) 0.44 (–0.96, 1.84) 
     P <0.0001, I
2
 = 60% P = 0.54 
       
Dong et al.  [60] 2013 1–24 9 418 –0.52(–0.9, –0.14) -2.08 (–3.25, –0.9) 
     P = 0.02, I
2
 = 57.2 P = 0.84, I
2
 = 0% 
       
 
I
2
, measure of heterogeneity (% of total variation due to heterogeneity rather than chance); WMD, weighted mean difference. 
  
